Comments*

 
  • Translational Research & Medicine

  • Events 

    Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM

    Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

    Speaker: Michael S. Conte (University of California-San Francisco), Milan Fiala (David Geffen School of Medicine at UCLA), Gabrielle Fredman (Columbia University), Bruce Levy (Harvard University, Brigham and Women's Hospital), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Harvard Medical School), Mauro Perretti (Queen Mary University of London), Charles N. Serhan (Brigham & Women's Hospital, Harvard Medical School), Patricia J. Sime (University of Rochester School of Medicine), Rudolph E. Tanzi (Massachusetts General Hospital)

    Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.

    Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM

    Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

    Speakers: Matthew D. Breyer (Eli Lilly, Indianapolis, IN), Frank C. Brosius (University of Michigan Medical School, Ann Arbor, MI), Benjamin D. Humphreys (Harvard Institutes of Medicine, Boston, MA), Matthias Meier (F. Hoffmann-LaRoche Ltd, Basel, Switzerland), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania, Philadelphia, PA), Aliza Thompson (US Food & Drug Administration, Silver Spring)

    Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.

    Tuesday, January 27, 2015 | 8:30 AM - 4:30 PM

    Growing Pains: The Future of Cytokines as Immunotherapies for Oncology, Infection and Inflammatory Disease

    Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School)
    Speakers: Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle MA), Dario Neri (Philogen, Zurich, Switzerland), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology)

    Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.

    Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM

    Harnessing the Potential of Genome Editing for Drug Discovery: Translational Frontiers of in vitro and in vivo Applications

    Speakers: James Inglese (National Center for Advancing Translational Sciences), Yi Yang (Novartis Institutes for Biomedical Research)

    The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.

  • Past Events

    Friday, October 10, 2014 | 8:00 AM - 3:15 PM

    New Frontiers in the Neurobiology of Mental Illness

    Sold Out
    Keynote Speaker: The Honorable Patrick J. Kennedy
    Former United States Representative, Rhode Island; One Mind for Research; Kennedy Forum

    This conference will explore the translation of recent breakthroughs in neuroscience into therapies for the more than twenty-five percent of Americans suffering from mental illnesses such as schizophrenia, depression, fear and anxiety disorders, autism, and other psychiatric disorders. A keynote lecture by The Honorable Patrick J Kennedy will address strategies to simultaneously abolish the stigma surrounding mental illness in order to fully realize the potential of these new treatments to improve mental health.

    Thursday, October 9, 2014 | 8:00 AM - 4:00 PM

    Targeting Key Vulnerabilities in Pancreatic Cancer

    Keynote Speakers: Neesha Dhani (Princess Margaret Hospital, Toronto), Steven D. Leach (Memorial Sloan Kettering Cancer Center)
    Speakers: Gregory Beatty (University of Pennsylvania Perelman School of Medicine), Neesha C. Dhani (Division of Medical Oncology & Hematology, University Health Network, Princess Margaret Cancer Centre/Ontario Cancer Institute), Mikala Egeblad (Cold Spring Harbor Laboratory), Douglas T. Fearon (Weill Cornell Medical College and Cold Spring Harbor Laboratory), Elda Grabocka (Department of Biochemistry and Molecular Pharmacology, NYU Langone School of Medicine), Costas A. Lyssiotis (Weill Cornell Medical College ), George Miller (NYU Langone Medical Center), Michael Ports (Gilead Sciences), Curtis B. Thompson (Halozyme Therapeutics, Inc)

    Pancreatic cancer patients currently have limited therapeutic options. This symposium explores breakthroughs in the pathogenesis and progression of pancreatic cancer, and efforts to exploit key vulnerabilities for novel therapeutic interventions.

    Tuesday, September 30, 2014 | 8:30 AM - 5:00 PM

    Elucidating GPCR Functional Selectivity: Novel Opportunities for Drug Development

    Keynote Speaker: Nobel Laureate Robert J. Lefkowitz (Duke University Medical Center)
    Speakers: John A. Allen (Pfizer), Laura Bohn (The Scripps Research Institute - Florida), Marc G. Caron (Duke University Medical Center), Jonathan A. Javitch (Columbia University and New York State Psychiatric Institute), Terry Kenakin (University of North Carolina School of Medicine), Bryan L. Roth (University of North Carolina School of Medicine), JoAnn Trejo (University of California, San Diego), Jonathan D. Violin (Trevena Inc.)

    Hear academic, industry, basic and translational researchers, including Nobel Laureate Robert Lefkowitz (Duke University Medical Center) and discuss the development of functionally selective GPCR-biased ligands for CV and CNS disease drug discovery.

    Thursday, September 11, 2014 | 8:00 AM - 2:00 PM

    From Bacterial Immunity to Genome Editing: The 2014 Dr. Paul Janssen Award Symposium

    Featuring Award Winners: Emmanuelle Charpentier (Helmholtz Centre for Infection Research) and Jennifer Doudna (Howard Hughes Medical Institute/University of California, Berkeley)

    Honor Drs. Emmanuelle Charpentier and Jennifer Doudna, recipients of the 2014 Dr. Paul Janssen Award for Biomedical Research.

  • Publications 

    Annals

    The 12th OESO World Conference: Cancers of the Esophagus

    Edited by Robert Giuli (Deputy Director of OESO, Executive Director of the OESO Foundation, Paris, France) and Asad Umar (National Cancer Institute, Rockville, Maryland)

    This Annals volume presents a compilation of expert views on topics related to esophageal cancers presented at the World Organization for Specialized Studies on Diseases of the Esophagus 12th World Conference.

    Volume 1325

    eBriefing

    Demyelination and Remyelination: From Mechanism to Therapy

    Keynote Speaker: Robin Franklin (Wellcome Trust – MRC Cambridge Stem Cell Institute, University of Cambridge)

    This eBriefing highlights biological and clinical findings in remyelination. It also features new techniques for imaging myelin and screening molecular targets, as well as therapeutics that promote remyelination.

    Annals

    Antimicrobial Therapeutics Reviews: Infectious Diseases of Current and Emerging Concern

    Edited by Karen Bush (Indiana University)

    The forth installment of this annual reviews series discusses the impact of infectious diseases (including carbapenem-resistant Enterobacteriaceae, tuberculosis, typhoid, influenza, and dengue) on the health of populations worldwide.

    Volume 1323

    Annals

    Annals Reports

    Edited by Annals of the New York Academy of Sciences editorial staff

    This Annals volume presents three meeting reports: (1) Production and supply of high-quality food protein for human consumption: sustainability, challenges, and innovations; (2) Clinical and economic outcomes of nutrition interventions across the continuum of care; and (3) Antibody–drug conjugates: an emerging modality for the treatment of cancer.

    Volume 1321

  • Webinar Archives

    Webinar Archive
    October 27, 2009

    Is Alzheimer's Disease Type 3 Diabetes?

    What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.

  • Translational Medicine Initiative

    Macy FoundationThe Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.

    Learn more at www.nyas.org/TransMed.